Charles River Laboratories International, Inc. Overview
Pro stress-test →Charles River Laboratories is a leading contract research organization (CRO) providing drug discovery, development, and manufacturing services to pharmaceutical and biotech clients. The company operates through three core segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions, supporting clients throughout the entire drug development lifecycle.
Strategic Profile
Pro stress-test →Charles River is repositioning its portfolio through strategic divestitures—notably completing the sale of its CDMO and Cell Solutions businesses in Q1 2026 (May 2026)—to focus on higher-margin discovery and research services. The company maintains market-leading positions in preclinical safety testing and research models, supported by extensive global infrastructure and scientific expertise.
Competitive Landscape
Pro stress-test →Charles River competes with major CROs including Parexel (Pamplona Capital), Covance/LabCorp Drug Development, Envigo (Inotiv), and IQVIA. The company differentiates through integrated service offerings across discovery, safety assessment, and manufacturing, along with proprietary research models and global laboratory infrastructure. Smaller specialized competitors exist in niche areas like contract manufacturing.
Industry Context
Charles River Laboratories International, Inc. operates in Contract Research Organizations (CRO) / Preclinical and Clinical Services.
Key facts
Founded: 1947 · Headquarters: Wilmington, MA, US · Revenue: $995.8M (Q1 2026)